anmelden
OMX Stockholm 30
3.258,14
PKT
+55,71
PKT
+1,74
%
Handle Aktien, ETFs, Derivate & Kryptos ohne Ordergebühren (zzgl. Spreads) beim ‘Kostensieger’ finanzen.net zero (Stiftung Warentest 12/2025)
Werbung
Analysen zu OMX Stockholm 30-Werten
| Datum | Rating | Analyst | |
|---|---|---|---|
| 16.01.18 | AstraZeneca Hold | Jefferies & Company Inc. | |
| 16.01.18 | Ericsson (Telefon L.M.Ericsson) (B) Neutral | UBS AG | |
| 15.01.18 | AstraZeneca Neutral | UBS AG | |
| 12.01.18 | ABB (Asea Brown Boveri) Conviction Buy List | Goldman Sachs Group Inc. | |
| 11.01.18 | Volvo (B) Underweight | Morgan Stanley | |
| 11.01.18 | ABB (Asea Brown Boveri) Neutral | Citigroup Corp. | |
| 11.01.18 | AstraZeneca buy | Deutsche Bank AG | |
| 10.01.18 | ABB (Asea Brown Boveri) Neutral | JP Morgan Chase & Co. | |
| 09.01.18 | ABB (Asea Brown Boveri) Hold | Société Générale Group S.A. (SG) | |
| 09.01.18 | Volvo (B) Hold | Société Générale Group S.A. (SG) | |
| 09.01.18 | ABB (Asea Brown Boveri) Neutral | Merrill Lynch & Co., Inc. | |
| 08.01.18 | AstraZeneca Neutral | UBS AG | |
| 05.01.18 | ABB (Asea Brown Boveri) Conviction Buy List | Goldman Sachs Group Inc. | |
| 05.01.18 | Volvo (B) Neutral | JP Morgan Chase & Co. | |
| 03.01.18 | ABB (Asea Brown Boveri) Neutral | JP Morgan Chase & Co. | |
| 29.12.17 | AstraZeneca overweight | JP Morgan Chase & Co. | |
| 20.12.17 | ABB (Asea Brown Boveri) Conviction Buy List | Goldman Sachs Group Inc. | |
| 14.12.17 | ABB (Asea Brown Boveri) kaufen | Kepler Cheuvreux | |
| 12.12.17 | Volvo (B) Neutral | UBS AG | |
| 12.12.17 | ABB (Asea Brown Boveri) Sell | UBS AG | |
| 11.12.17 | ABB (Asea Brown Boveri) Conviction Buy List | Goldman Sachs Group Inc. | |
| 08.12.17 | Volvo (B) Neutral | Goldman Sachs Group Inc. | |
| 05.12.17 | AstraZeneca buy | Deutsche Bank AG | |
| 04.12.17 | ABB (Asea Brown Boveri) buy | Deutsche Bank AG | |
| 02.12.17 | Hennes Mauritz (H M, H&M) Neutral | Goldman Sachs Group Inc. | |
| 01.12.17 | AstraZeneca Equal-Weight | Morgan Stanley | |
| 30.11.17 | AstraZeneca Neutral | JP Morgan Chase & Co. | |
| 29.11.17 | ABB (Asea Brown Boveri) Conviction Buy List | Goldman Sachs Group Inc. | |
| 29.11.17 | ABB (Asea Brown Boveri) overweight | Barclays Capital | |
| 24.11.17 | ABB (Asea Brown Boveri) Conviction Buy List | Goldman Sachs Group Inc. | |
| 24.11.17 | ABB (Asea Brown Boveri) Neutral | JP Morgan Chase & Co. | |
| 20.11.17 | ABB (Asea Brown Boveri) Conviction Buy List | Goldman Sachs Group Inc. | |
| 16.11.17 | AstraZeneca Reduce | HSBC | |
| 14.11.17 | ABB (Asea Brown Boveri) Equal-Weight | Morgan Stanley | |
| 10.11.17 | AstraZeneca Equal-Weight | Morgan Stanley | |
| 10.11.17 | AstraZeneca Hold | S&P Capital IQ | |
| 09.11.17 | AstraZeneca Neutral | UBS AG | |
| 08.11.17 | AstraZeneca buy | Citigroup Corp. | |
| 08.11.17 | Ericsson (Telefon L.M.Ericsson) (B) Neutral | JP Morgan Chase & Co. | |
| 08.11.17 | ABB (Asea Brown Boveri) overweight | Barclays Capital |
* Die angezeigten Realtime Kurse sind indikativ und nicht die offiziellen Börsenkurse. Die Kursdaten können eventuell vom tatsächlichen Marktpreis abweichen.
